
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Preapproval from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/preapproval/topic/12060/</link>
        <description>Articles tagged with Preapproval from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>BI, Lilly go simple in new SGLT med-ed effort</title>
          <description>Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&amp;J&apos;s SGLT2 inhibitor Invokana.</description>
          <link>http://www.mmm-online.com/bi-lilly-go-simple-in-new-sglt-med-ed-effort/article/292257/</link>
          <pubDate>Tue, 07 May 2013 14:03:31 GMT</pubDate>
          <itunes:summary>Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&amp;J&apos;s SGLT2 inhibitor Invokana.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>BMS, Abbott HCV pill data suggest competition for Gilead</title>
          <description>Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.</description>
          <link>http://www.mmm-online.com/bms-abbott-hcv-pill-data-suggest-competition-for-gilead/article/263850/</link>
          <pubDate>Tue, 16 Oct 2012 16:02:56 GMT</pubDate>
          <itunes:summary>Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Boehringer Ingelheim prepares to launch oncology franchise</title>
          <description>Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That&apos;s about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.</description>
          <link>http://www.mmm-online.com/boehringer-ingelheim-prepares-to-launch-oncology-franchise/article/261919/</link>
          <pubDate>Tue, 02 Oct 2012 19:46:09 GMT</pubDate>
          <itunes:summary>Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That&apos;s about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  